| Title |
Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
|
|---|---|
| Published in |
Drug Design, Development and Therapy, October 2017
|
| DOI | 10.2147/dddt.s114932 |
| Pubmed ID | |
| Authors |
Francesca Cinti, Simona Moffa, Flavia Impronta, Chiara MA Cefalo, Vinsin A Sun, Gian Pio Sorice, Teresa Mezza, Andrea Giaccari |
| Abstract |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides greater cardiovascular protection, combined with a reduction in body weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 81 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 17 | 21% |
| Student > Master | 10 | 12% |
| Student > Ph. D. Student | 7 | 9% |
| Researcher | 5 | 6% |
| Other | 3 | 4% |
| Other | 10 | 12% |
| Unknown | 29 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 36% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Agricultural and Biological Sciences | 4 | 5% |
| Nursing and Health Professions | 3 | 4% |
| Other | 7 | 9% |
| Unknown | 29 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2020.
All research outputs
#2,795,236
of 25,382,440 outputs
Outputs from Drug Design, Development and Therapy
#149
of 2,268 outputs
Outputs of similar age
#51,539
of 331,218 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 44 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,218 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.